You can make an appointment with the barnaclínic+ FASD Unit online. Once you have made your request, we will contact you, attempting to take your preferences into account as much as possible.
THE UNIT
The FASD unit has specific expert equipment for the diagnosis and monitoring of Foetal Alcohol Spectrum Disorder, including clinical guidelines for parents and schools, an app for clinical diagnosis, etc.
Leaded by Dr. Oscar García-Algar, it is the only unit of its kind in Spain and it works directly (under the umbrella of BCNatal) with the staff at Hospital Sant Joan de Déu, where its other premises are located.
TEACHING AND RESEARCH
In addition to the clinical aspect, the unit carries out FASD teaching activities and research. Our clinical research group - Grup de Recerca Infància i Entorn (GRIE) - has more than 15 years of experience on the subject and is a national and international leader in clinical research on alcohol exposure during pregnancy.
We are the main national FASD clinical research group, with public and private funding, covering 4 main lines of research: clinical care, basic research, clinical trials with therapeutic candidates, animal models on the effects of prenatal exposure to alcohol on neurodevelopment.
TREATMENT LINES
What is FASD?
Alcohol is one of the most teratogenic substances and its consumption during pregnancy may lead to a wide range of adverse effects on the developing foetus. Prenatal exposure to alcohol causes dysfunction of the central nervous system (CNS) due to structural and functional brain damage.
In some cases these structural changes may be viewed using Magnetic Resonance Imaging, the most common being microcephaly, reduction in the volume of white and grey matter, malformation and agenesis of the corpus callosum, reduction in the volume of the caudate nucleus, hippocampus and the frontal, temporal and parietal lobes.
The severity of the damage due to prenatal exposure to alcohol depends primarily on the dose consumed and the time and pattern of consumption, as well as individual genetic susceptibility.
Hence, Foetal Alcohol Spectrum Disorder (FASD) groups the following conditions into various clinical forms: Full Foetal Alcohol Syndrome (FAS), partial FAS, alcohol-related birth defects (ARBD) and Alcohol-related neurodevelopmental disorder (ARND).

Symptoms of FASD
Foetal Alcoholic Spectrum Disorder merely describes a series of clinical conditions that make it possible to diagnose the damage caused by prenatal alcohol. FASD itself has no specific treatment, since it is syndromic.
Even so, no single cognitive profile pattern has been identified that can be considered prototypical; some of the disorders that are more common in children with FASD include involvement of working memory, emotional management difficulties and theory of mind deficits.
At a clinical level, these difficulties result in various degrees of signs and symptoms such as attention deficit and hyperactivity disorder (ADHD), academic failure, mental retardation, problems reading and writing, behavioural problems, etc., although all of these are not always presented or with the same intensity. Each child with FASD has a different neuropsychological and behavioural profile.
Treatment of FASD
Treatment of Foetal Alcoholic Spectrum Disorder is mainly psychological (cognitive-behavioural), logopedic, educational and, in exceptional circumstances, pharmacological (always symptomatic, as there is currently no specific FASD treatment for the underlying FASD lesion). The family must always be offered psychological support. The comprehensive follow-up of patients is conducted using several types of visit: pre-adoption, post-adoption, diagnostic, follow-up, case studies, coordination with professionals and resources.
OUR OFFER
FASD PACK |
|
|
1. Pre-adoption: initial visit prior to adoption which includes general information about adoption, risks, evaluation of reports, images, videos, etc., and counselling prior to adoption |
60 min. |
|
2. Post-adoption: basically, this is the visit after adoption, almost exclusively for confirmation or exclusion of the FASD diagnosis, which includes an evaluation of the reports, physical assessment, psychological tests, devolution tests, etc., focus of follow-up, coordination with professional |
60 min. |
|
3. Diagnosis of FASD: Includes prior, psychologist, paediatric and devolution visits, as well as coordination with professionals. |
120 min. |
FIRST VISIT |
|
|
1. Psychology |
90 min. |
|
2. Non-specific assessment: for example, second opinion, first post-diagnosis visit after diagnosis of FASD, etc. |
60 min. |
|
3. Post-adoption |
60 min. |
FOLLOW-UP VISIT |
|
|
1. Psychology (weekly, fortnightly or monthly) 2. Non-specific assessment 3. Coordination (school, professionals, etc.) |
60 min. |
You can make an appointment with the barnaclínic+ FASD Unit online. Once you have made your request, we will contact you, attempting to take your preferences into account as much as possible.
How to arrive
Blog

New PRP treatment for persistent loss of smell at barnaclínic+
Loss of smell, or anosmia, is quite common after viral infections such as COVID-19. When it lasts more than a year and does not improve with conservative treatment, platelet-rich plasma (PRP) may be an option for recovering the sense of smell. Many patients regain this sense spontaneously within weeks or months, but if there has […]

Teplizumab, a new treatment to delay the onset of type 1 diabetes, now available at barnaclínic+
barnaclínic+ now offers Teplizumab (Teizeild®), a new treatment for type 1 diabetes that can delay the onset of clinical diabetes in certain patients who have not yet developed symptoms. This new biological therapy represents a paradigm shift in the management of type 1 diabetes, as it makes it possible to target the autoimmune process responsible […]

Donanemab, a new treatment for Alzheimer’s disease now available at barnaclínic+
barnaclínic+ is expanding its treatment options for Alzheimer’s disease with donanemab (Kisunla®), a new treatment for patients in the early stages of the disease. This monoclonal antibody targets build-ups of beta-amyloid protein in the brain and has been shown to slow the progression of cognitive and functional decline in certain patients. The availability of donanemab […]